Efficacy of Changing to DuoTrav® (Travoprost 0.004%/Timolol 0.5% BAK-Free Fixed Combination) From Prior Therapy

Inclusion Criteria: * Clinical diagnosis of ocular hypertension, open-angle glaucoma, or pigment dispersion glaucoma in both eyes. * On a stable IOP-lowering regimen of prostaglandin fixed combination (either Xalacom or Ganfort) within 4 weeks prior to the Screening Visit. * IOP between 19 and 35 mmHg at any time of day in at least 1 eye. * Best corrected visual acuity (BCVA) of 6/60 (20/200 Snellen; 1.0 LogMAR) or better in each eye. * Willing to discontinue the use of all other ocular hypotensive medication(s) prior to receiving the study medication for the entire course of the study. * Other protocol-defined inclusion criteria may apply. Exclusion Criteria: * Known medical history of allergy, hypersensitivity, or poor tolerance to any component of DuoTrav® deemed clinically significant in the opinion of the Principal Investigator. * Corneal dystrophies in either eye. * Risk of visual field or VA worsening as a consequence of participation in the study, in the investigator's best judgment. * Any disease or condition that would preclude the safe administration of a topical beta-blocker, present a special risk to the subject, or interfere with optimal participation in the study. * Women who are pregnant or lactating. * Participation in any other investigational study within 30 days prior to the Screening Visit. * Other protocol-defined exclusion criteria may apply.